The numbers behind post-traumatic stress disorder, or PTSD, are more shocking than you know. The World Health Organization (WHO) estimates that about one in twenty trauma sufferers go on to develop PTSD. Forty percent recover within a year. Only a quarter of people with PTSD seek care.
These statistics have motivated the scientific community to explore alternative treatment options, like psilocybin, which is emerging as an unexpected candidate. Also known as magic mushrooms, psilocybin is a potential pathway for PTSD sufferers who haven’t had success with other treatments, or can’t access care in the first place.
The science is still in its infancy, but the signals are promising. Here’s what we know about psilocybin for PTSD.
It’s important to understand what qualifies as PTSD. Feeling distressed or having mental health difficulties after a traumatic experience doesn’t necessarily qualify as PTSD. Per the WHO:
“Someone experiences PTSD when they have symptoms re-experiencing the event, avoid reminders of the event, experience symptoms of heightened arousal that cause significant distress, and interfere with daily activities and family, social, school or working life.”
On a neurological level, PTSD is associated with hyperactivity in the amygdala, a small area of your brain that is primarily responsible for managing emotions like fear, anxiety, and apprehension. An overactive amygdala dampens other areas of the brain, like the prefrontal cortex, preventing your mind from accurately assessing and weighing threats.
PTSD is an intractable condition. There are few interventions currently available which provide stable relief, as PTSD influences your brain to constantly rewire itself in a detrimental attempt at protecting from threats. It’s messy, noisy, and constant.
Psychedelics like psilocybin may be able to cut through the “neurological static” of PTSD. But they’re not a cure in the literal sense - psychedelic-assisted therapies, or PAT, may help sufferers engage with traumatic memories differently than conventional approaches.
It’s all about neuroplasticity. Psychedelic drugs like magic mushrooms excite the brain, temporarily encouraging disparate or dormant regions to communicate or quiet down. Psilocybin is believed to affect both an overactive amygdala and something called the Default Mode Network, or DMN.
The DMN is a bit like a mental screen-saver. It comes online and locks the brain into whatever thought loops are already present. For those with PTSD, this can manifest as feeling trapped in a downward spiral of dread.
Recently, researchers have begun to see the clinical potential of psilocybin in greasing the proverbial gears. A 2022 systematic review remarked that classical psychedelics seem to be able to “modulate” the DMN, conferring improved mental health and well-being. Other research indicates that psilocybin can reduce rumination, which is linked to PTSD symptoms.
It’s worth mentioning that psilocybin for PTSD is an emerging field of study. Most of the PAT studies relating to PTSD have used MDMA, but there’s some merit to both ketamine and ayahuasca, too.
However, in 2024, those advancements started encountering regulatory roadblocks that, thankfully, are beginning to clear. In the interim, attention on psychedelics for PTSD has turned elsewhere.
Psilocybin has a large and still growing body of evidence behind it as an alternative intervention for conditions like treatment-resistant depression. For PTSD, things are less certain, but current findings and planned studies are compelling.
At this point, classical psychedelics have clear clinical potential. They may even be an alternative option for those suffering from complex mental illnesses who cannot find relief elsewhere. For PTSD sufferers - a majority of whom do not seek help via conventional means - psychedelics might be a legitimate lifeline.
However, it’s wise to keep hopes and expectations in check. As of now, there are no large-scale, longitudinal trials on psilocybin for PTSD. Robust, long-term, peer-reviewed evidence of that nature is a prerequisite for mass approval. As such, psilocybin isn’t likely to be an accessible option for most people in the near future.
The existing data and planned trials are encouraging, but there simply isn’t a reliable verdict - yet. In the interim, some sufferers opt to engage with psychedelic therapies at psychedelic retreats. Retreats are often held abroad, in countries with more permissive laws or tolerant sensibilities.
While not subject to regulatory oversight, psychedelic retreats employ teams of qualified facilitators and medical staff trained to maximize the potential of psychedelics while minimizing risk.